Navigation Links


Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board

12/17/2014
AUSTIN, Texas , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: VRML ), a bio-analytic solutions company focused on gynecologic disease, today announced the next step in its expanded strategy to rebuild the company into a premier bio-analytics solutions provider with the naming of current Chief Operating Officer, Valerie Palmieri to President and Chief Executive Officer, whil... [Comments]

United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change

12/17/2014
SILVER SPRING, Md. , Dec. 17, 2014  United Therapeutics Corporation (NASDAQ: UTHR ) announced today two senior executive promotions as well as changes to Martine Rothblatt , Ph.D's compensation program. Senior Executive Promotions United Therapeutics announced the promotion of Roger Jeffs , Ph.D. to President and Co-Chief Executive Officer and David Zaccardelli... [Comments]

CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma

12/17/2014
ROCKVILLE, Md. , Dec. 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary commercial focus on China , today reported that it has been granted a Type C meeting with the U... [Comments]

Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus

12/17/2014
SOUTH SAN FRANCISCO, Calif. , Dec. 17, 2014 Tigercat Pharma, Inc. today announced positive results of a Phase 2 study evaluating the investigational oral NK-1 receptor antagonist VPD-737 (serlopitant), for the treatment of patients with severe, chronic itch who are unresponsive or inadequately responsive to the current standard of care, including topical steroids and antihista... [Comments]

Synageva BioPharma To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12, 2015 at 9:00 a.m. PST

12/17/2014
LEXINGTON, Mass. , Dec. 17, 2014   Synageva BioPharma Corp. (NASDAQ: GEVA ), a biopharmaceutical company developing therapeutic products for rare disorders, announced today its presentation at the upcoming J.P. Morgan Healthcare Conference being held in San Francisco, CA. Sanj K. Patel , President and Chief Executive Officer, will present on Monday, January 12, 2... [Comments]

New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO

12/15/2014
(PRWEB) December 15, 2014 METTLER TOLEDO is pleased to announce that the next-generation inline PVM tool, ParticleView V19 with PVM technology , is now available. The new in situ probe-based particle vision and measurement tool continuously captures high-resolution images under a wide range of process conditions. ParticleView V19 then automatically prepares a report pairing the most releva... [Comments]

BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office

12/15/2014
NEW YORK & PETACH TIKVAH, Israel , Dec. 15, 2014  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant of approximately $1.1 million from Israel's Office of the Chief Scientist (OC... [Comments]

Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product

12/15/2014
SAN DIEGO , Dec. 15, 2014 Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology,  today celebrated continued positive reception by the industry and collaborators of its exVive3D TM Human Liver Tissue.  The product, which was made widely available in full commercial rele... [Comments]

AeroScout Founder Joins GlassesOff's Board of Directors

12/15/2014
NEW YORK , Dec. 15, 2014  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment of Mr. Yuval Bar-Gil as an independent director of the Company's Board of Directors. Mr. Bar-Gil was founder of AeroScout and served as its CEO until its acquisition by Stanley Black & Decker in 2012, a $240 million transaction. Recognized as the inventor of the first Wi-Fi-ba... [Comments]

Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015

12/15/2014
BEIJING , Dec. 15, 2014  Origin Agritech Limited (NASDAQ GS: SEED) (" Origin ", or the " Company "), a technology-focused supplier of crop seeds in China , today announced that the Company will report results for its fiscal year 2014 ended September 30, 2014, before the market opens on Thursday, January 8, 2015. The Company will host a teleconference on January 8, 201... [Comments]

[previous] [next]
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... recent surge of DNA sequence information resulting from deciphering ... for innovative technological developments that have been vital in ... has allowed for the development of novel genetic therapies ... The new genomic era heralds earlier diagnoses, greatly ...
... fluorescence is an effective way of determining how ... technique described in the open access journal ... a quantitative and precise determination of viability in ... demands of industrial, municipal and agricultural consumption on ...
... widespread in the animal kingdom than previously thought. A ... fiddler crabs "lie" about their fighting ability by growing ... fact weak and puny. Published this week in the ... study is the first direct evidence that crabs "bluff" ...
Cached Biology News:Personalized medicine: Innovative online journal leads the way 2Fiddler crabs reveal honesty is not always the best policy 2Fiddler crabs reveal honesty is not always the best policy 3
... for western blots ,• Optically clear plastic ... staining western blots. The reduced size (60 ... disposable tray requires less dye and antibodies ... the user. Pour spouts in each corner ...
... pLivSelect is a ... for recombinant identification. Recombinant ... colony survival, eliminating the ... screening. This quick and ...
... Qentix Western Blot Signal Enhancer does for enzyme-/substrate-based ... it increases the signal up to 10-fold ... minutes., ,The Western Blot Signal Enhancer membrane ... be added to your current Western blotting ...
... Solid phase extraction through columns is ... range of applications. Typical applications are in ... in diagnostics, or compound purification in chemical ... fully automated on the Genesis series instruments ...
Biology Products:
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
(Date:12/15/2014)... -- GlassesOff Inc. (OTCBB: GLSO) announced today the appointment of ... of the Company,s Board of Directors. Mr. ... CEO until its acquisition by Stanley Black ... as the inventor of the first Wi-Fi-based Active RFID ... RFID solutions focused on improving operational efficiency, safety and ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
(Date:12/13/2014)... /CNW/ - MaRS and Virgin Unite Canada, the non-profit foundation ... forces to support Canadian entrepreneurs tackling social and environmental challenges. ... at the MaRS Centre to announce the new partnership, which ... This fund has $1 million in seed capital provided by ... Mindset Social Innovation Foundation, founded by Alison Lawton . ...
Breaking Biology Technology:BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... SeqWright Inc., a world-wide leader in custom genomic ... strides to position itself as the Next-Generation Sequencing ... can be attributed to the company,s ability to ... in key genomics technologies. Building on this success, ...
... 11, 2011 Regenicin, Inc. (OTC Bulletin Board: ... development of regenerative cell therapies to restore the health ... 4th annual OneMedForum at the Sir Francis Drake Hotel ... Randall McCoy, will present Regenicin,s core business model and ...
... 2011 AstraZeneca (NYSE: AZN ) and ... advancing therapies for cancer patients through clinical research, today ... a novel targeted oncology compound from AstraZeneca. ... accounting for 7.4 million (or 13%) of all deaths ...
Cached Biology Technology:SeqWright Continues Expansion of Next-Generation Sequencing Capabilities 2Regenicin CEO to Participate in Live Webcast at OneMedForum Business Development and Finance Conference, January 11th at 4:00 PM PST 2AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer 2AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer 3